Skip to main content
. Author manuscript; available in PMC: 2013 Jul 15.
Published in final edited form as: Clin Cancer Res. 2012 Jun 4;18(14):3942–3951. doi: 10.1158/1078-0432.CCR-11-2856

Table 1.

Summary of the overall study design and results.

Findings
SNPs Analyzed Study
Samples		 Risk Analysis Survival Analysis
Seven (7) SNPs identified by previous genome-wide association study of pancreatic cancer risk (refs. 3–5) 531 cases, 305 controls
(MSKCC)		 Independent replication of the risk associations of SNPs:

rs505922 (chr 9q34, ABO)
rs9543325 (chr 13q22)		 no significant findings
Twenty-four (24) SNPs identified by previous candidate-gene/pathway studies of pancreatic cancer clinical outcome (refs. 6–17) 513 cases
(MSKCC)		 no significant findings Independent replication of the overall survival association of SNP:

rs9350 (chr 1q43, EXO1)
Genome-wide association study of
overall survival from pancreatic
cancer (this study)		 not performed Putative identification of a novel SNP associated with overall survival:

rs1482426 (chr 12q21)
    Stage 1 (Discovery): 301,250 SNPs 252 cases
(MSKCC)
    Stage 2 (Validation): 22 SNPs 261 cases
(MSKCC)
    Stage 3 (Replication): 1 SNP 572 cases
(Mayo Clinic)